143 related articles for article (PubMed ID: 28512072)
1. Lessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective.
Beppu H; Minaguchi M; Uchide K; Kumamoto K; Sekiguchi M; Yaju Y
Indian J Med Ethics; 2017; 2(2):82-88. PubMed ID: 28512072
[TBL] [Abstract][Full Text] [Related]
2. The controversy on HPV vaccination in Japan: Criticism of the ethical validity of the arguments for the suspension of the proactive recommendation.
Okita T; Enzo A; Kadooka Y; Tanaka M; Asai A
Health Policy; 2020 Feb; 124(2):199-204. PubMed ID: 31924344
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
4. HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine.
Sawada M; Ueda Y; Yagi A; Morimoto A; Nakae R; Kakubari R; Abe H; Egawa-Takata T; Iwamiya T; Matsuzaki S; Kobayashi E; Yoshino K; Kimura T
Int J Clin Oncol; 2018 Feb; 23(1):121-125. PubMed ID: 28986659
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?
Tomljenovic L; Shaw CA
Ann Med; 2013 Mar; 45(2):182-93. PubMed ID: 22188159
[TBL] [Abstract][Full Text] [Related]
7. Indian MPs criticise HPV vaccination project for ethical violations.
Mudur G
BMJ; 2013 Sep; 347():f5492. PubMed ID: 24014444
[No Abstract] [Full Text] [Related]
8. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
9. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
10. Human papilloma virus vaccine for low and middle income countries: A step too soon?
Jindal HA; Kaur A; Murugan S
Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine: a paradigm shift for pediatricians.
Jenson HB
Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
[TBL] [Abstract][Full Text] [Related]
12. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
14. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
16. Indications and efficacy of the human papillomavirus vaccine.
Hakim AA; Lin PS; Wilczynski S; Nguyen K; Lynes B; Wakabayashi MT
Curr Treat Options Oncol; 2007 Dec; 8(6):393-401. PubMed ID: 18172770
[TBL] [Abstract][Full Text] [Related]
17. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
[TBL] [Abstract][Full Text] [Related]
18. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
19. Contents of Japanese pro- and anti-HPV vaccination websites: A text mining analysis.
Okuhara T; Ishikawa H; Okada M; Kato M; Kiuchi T
Patient Educ Couns; 2018 Mar; 101(3):406-413. PubMed ID: 29031425
[TBL] [Abstract][Full Text] [Related]
20. [Expert consensus on immunological prevention of human papillomavirus-related diseases].
Vaccine and Immunization Branch, Chinese Preventive Medicine Association
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Aug; 53(8):761-803. PubMed ID: 31378039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
